UNC3230
UNC3230 性质
| 储存条件 | Store at -20°C |
|---|---|
| 溶解度 | DMSO:30.0(最大浓度 mg/mL);87.1(最大浓度 mM) DMF:30.0(最大浓度 mg/mL);87.1(最大浓度 mM) 乙醇:0.2(最大浓度 mg/mL);0.58(最大浓度 mM) |
| 形态 | 结晶固体 |
| 颜色 | 米白色至浅黄色 |
| InChIKey | RZCNASHHHSKTGP-UHFFFAOYSA-N |
| SMILES | O=C(N)C1=C(NC(C2CCCCC2)=O)SC(NC3=CC=CC=C3)=N1 |
UNC3230 用途与合成方法
IC50: ~41 nM (Phosphatidylinositol 4-phosphate 5 kinase type 1C (PIP5K1C))
Membrane PIP2 levels are significantly reduced by ~45% in dorsal root ganglia (DRG) neurons treated with 100 nM UNC3230 (~2-fold above the IC50) relative to vehicle controls. UNC3230 significantly reduces lysophosphatidic acid (LPA)-evoked calcium signaling in cultured DRG neurons relative to vehicle.
UNC3230 (2 nmol) significantly increases noxious heat-evoked paw withdrawal latency for two hours after intrathecal injection in wild-type mice, indicating an antinociceptive effect.
UNC3230 (2 nmol; intrathecal injection) is administered then one hour later co-injected 1 nmol LPA with UNC3230 (2 nmol, intrathecal injection). UNC3230 significantly blunts thermal hyperalgesia and mechanical allodynia compared to vehicle.
UNC3230 (2 nmol; intrathecal injection) significantly blunts thermal hyperalgesia and mechanical allodynia in the complete Freund’s adjuvant (CFA)-inflamed hindpaw (relative to vehicle control) but does not affect thermal or mechanical sensitivity in the control (non-inflamed) hindpaw over a multiday time course.
UNC3230 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2026-09-15 | HY-110150 | 1031602-63-7 | 1 mg | 590 | |
| 2026-09-15 | HY-110150 | UNC3230 | 1031602-63-7 | 5mg | 1200 |
